Global Gut Microbiota Trends

Frost & Sullivan Publishes Comprehensive White Book on Gut Microbiota Industry Trends

Frost & Sullivan has published a White Book on the Current Landscape and Future Trends of the Gut Microbiota Industry. The study provides a comprehensive overview of the gut microbiota's relationship with health and disease, the current landscape of gut microbiota drug development, market insights, and future trends. Live Biotherapeutic Products (LBPs) are biologics derived from live organisms intended for the prevention, treatment, or cure of human diseases. These products must meet pharmaceutical development standards, have clearly defined indications, and undergo rigorous evaluations of safety, efficacy, chemistry, manufacturing, and controls (CMC), as well as clinical performance. Clinical trials for gut microbiota-based therapeutics are primarily concentrated in China, the United States, Europe, and Canada. The industry has achieved breakthrough advances through interdisciplinary collaboration and technological innovation. China ranks first globally in the number of microbiota-related patent applications, accounting for 33% of the total.